Try a new search

Format these results:

Searched for:

in-biosketch:true

person:pomarn01

Total Results:

213


Transient elevations in pancreatic enzymes in response to a cholinesterase inhibitor [Letter]

Pomara N; Citrome L
PMID: 8665561
ISSN: 0362-5664
CID: 23688

THE EFFECT OF NORTRIPTYLINE ON VERBAL RECALL [Meeting Abstract]

POMARA, N; NOLAN, K; DEPTULA, D; PESELOW, E; COOPER, TB
ISI:A1995QX03700072
ISSN: 0006-3223
CID: 87283

Detecting Alzheimer's disease [Comment]

Pomara N; Sitaram N
PMID: 7886438
ISSN: 0036-8075
CID: 23689

CSF CONCENTRATIONS OF CRF IN ALZHEIMERS-DISEASE AND NORMAL-PRESSURE HYDROCEPHALUS [Meeting Abstract]

POMARA, N; BISSETTE, G; GOLOMB, J; TARSHISH, C; INCE, C; DESIMONE, P; FERRIS, S; DELEON, M
ISI:A1994NV60900501
ISSN: 0197-4580
CID: 52409

Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease

Loeffler DA; DeMaggio AJ; Juneau PL; Brickman CM; Mashour GA; Finkelman JH; Pomara N; LeWitt PA
Although the pathophysiology of Alzheimer's disease (AD) and Parkinson's disease (PD) is unknown, altered brain antioxidative mechanisms have been found in both disorders. Ceruloplasmin (CP) and transferrin (TF) interact to limit concentrations of free ferrous iron (Fe2+), and thus play an important role in antioxidant defense in serum; both proteins are also produced in brain, where their significance as antioxidants is unknown. We quantified concentrations of CP and TF by immunoassay in AD (n = 17) and PD (n = 12) cerebrospinal fluid (CSF) to determine whether these proteins could serve as disease markers. CP was increased versus aged normal subjects (n = 11) in AD (p < 0.05) but not PD CSF, whereas TF concentrations did not differ between groups. CP levels have been reported to be elevated in some brain regions in AD, and increased CP in AD CSF may reflect this finding. Systemic inflammation and oxidative stress are major factors stimulating hepatic CP synthesis, and it remains to be determined whether increased CP concentrations in AD CSF and brain follow from similar mechanisms
PMID: 7986488
ISSN: 0893-0341
CID: 23690

Caregivers and stress-related neurotransmitter changes

Chapter by: Chou, James C.-Y; Deptula, Dennis; Singh, Rajkumar; Pomara, Nunzio
in: Stress effects on family caregivers of Alzheimer's patients: Research and interventions by Light, Enid [Eds]
New York, NY, US: Springer Publishing Co, 1994
pp. 93-114
ISBN: 0-8261-7890-1
CID: 4794

Aging, emotional states, and memory

Deptula D; Singh R; Pomara N
OBJECTIVE: This study compared the relation between negative mood states and memory in young and elderly subjects. METHOD: Forty-five normal, healthy young volunteers (ages 19-35 years) and 45 normal, healthy elderly volunteers (ages 60-78 years) were administered a verbal list-learning task and self-rated scales of affective states. RESULTS: The elderly group, but not the young group, consistently exhibited significant correlations between their performance on verbal recall measures and their ratings of their anxiety, depression, and withdrawal; i.e., within the elderly group, higher levels of negative affective states were associated with poorer memory. CONCLUSIONS: These findings indicate that aging modulates the relation between emotional state and memory functions, and they are consistent with the hypothesis that the elderly are more vulnerable than the young to the adverse effects of negative emotional states on memory. Therefore, even in normal elderly individuals without diagnosable psychopathology, negative affective states (such as anxiety and depression) may interfere with memory functioning
PMID: 8434658
ISSN: 0002-953x
CID: 23691

EFFECT OF NICOTINE AND YOHIMBINE ON THE RELEASE OF [H-3] NOREPINEPHRINE FROM RAT HIPPOCAMPAL SLICES [Meeting Abstract]

ZELLES, T; SERSHEN, H; LAJTHA, A; POMARA, N; VIZI, ES
ISI:A1993LM56500104
ISSN: 0022-3042
CID: 115503

Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type

Dysken MW; Mendels J; LeWitt P; Reisberg B; Pomara N; Wood J; Skare S; Fakouhi JD; Herting RL
OBJECTIVE: Milacemide, a MAO-B inhibitor that is also a prodrug for glycine, was tested as a treatment for senile dementia of the Alzheimer type (SDAT) because of its potential for enhancing cognition in animal models of impaired learning and memory. DESIGN: Double-blind, placebo-controlled, randomized clinical trial. SETTING: Sixteen study sites, both university-affiliated and private. PATIENTS: A total of 228 outpatients (116 men and 112 women) with SDAT, ranging in age from 49-93 years. INTERVENTION: 1200 mg/day milacemide treatment for 1 month (113 patients received milacemide, and 115 patients received placebo). MAIN OUTCOME MEASURES: Alzheimer's Disease Assessment Scale and the Mini-Mental State Examination. RESULTS: Milacemide-treated SDAT patients did not show significant improvement in any of the outcome measures used. Significant elevations in liver enzymes in four subjects were of sufficient magnitude to necessitate withdrawal from the study. CONCLUSIONS: Milacemide does not appear to be an effective treatment in enhancing cognition in SDAT patients
PMID: 1634705
ISSN: 0002-8614
CID: 23692

Glutamate and other CSF amino acids in Alzheimer's disease

Pomara N; Singh R; Deptula D; Chou JC; Schwartz MB; LeWitt PA
The authors compared CSF amino acid levels of 10 patients with mild to moderate dementia and probable Alzheimer's disease who had never received antidepressant or neuroleptic medication with those of 10 normal subjects of similar age. The Alzheimer's patients had significantly higher levels of CSF glutamate. This finding was not related to age, sex, or severity of dementia. Elevated CSF glutamate may reflect greater glutamatergic activity early in the course of Alzheimer's disease. The authors speculate that the excitotoxic effects of glutamate may contribute to progressive neuronal loss in Alzheimer's disease
PMID: 1734749
ISSN: 0002-953x
CID: 23693